PCGF2 and breast cancer: More recently, MEL-18 loss was described as mediating estrogen receptor-α (ER-α) downregulation, resulting in a hormone-independent phenotype of breast cancer associated with poor prognosis, implicating a key role in the hormonal regulation of breast cancer [245].